937048-39-0

Basic information

• Product Name: (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid
• Synonyms: (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid;3-(4-(tert-butoxycarbonyl)piperazin-l-yl)phenylboromc acid
• CAS NO: 937048-39-0
• Molecular Formula: C₁₅H₂₃BN₂O₄
• Molecular Weight: 306.16512
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate
• Mol File: 937048-39-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid(937048-39-0)
• EPA Substance Registry System: (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid(937048-39-0)

Safety Data

• Hazardous Substances Data: 937048-39-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid serves as a key reagent in organic synthesis, utilized for the formation of carbon-carbon and carbon-heteroatom bonds. Its presence aids in creating complex molecular structures that are otherwise challenging to synthesize.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid is used as a precursor in the development of new drugs. (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid's structure, particularly the piperazine ring, makes it a candidate for designing medications aimed at treating central nervous system disorders.
Used in Materials Science:
(3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid also finds applications in materials science. Its unique properties allow it to be integrated into the development of new materials with specific characteristics, such as those with potential applications in nanotechnology or as components of advanced composites.
Safety Precautions:
When handling (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid, it is crucial to take safety measures to avoid exposure. (3-[4-(tert-Butoxycarbonyl)piperazin-1-yl]phenyl)boronic acid is toxic and can cause irritation to the skin and eyes. Therefore, it should be manipulated in a controlled environment, with appropriate personal protective equipment, to minimize health risks.

Upstream product

• 5419-55-6 Triisopropyl borate 
• 327030-39-7 1,1-dimethylethyl 4-(3-bromophenyl)piperazine-1-carboxylate 
• 108-36-1 1,3-dibromobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1234367-53-3 tert-butyl 4-(3-(2,6-dichloroquinazolin-4-yl)phenyl)piperazine-1-carboxylate 
• 937048-40-3 4-[3-(4-amino-pyrrolo[2,1-f][1,2,4]triazin-7-yl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

CaMKII INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of Ca2+/calmodulindependent protein kinase (CaMKII), compositions thereof, and methods of using the same. Cardiovascular disease remains the number one cause of death in developed countries. Furthermore, incidence of cardiovascular disease has increased dramatically in developing countries. Although cardiovascular disease usually affects older adults, the antecedents of cardiovascular disease, notably atherosclerosis, begin in early life, making primary prevention efforts necessary from childhood.

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract

1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors

Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.